EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Combining Guselkumab with Upadacitinib Is Safe and Effective in the Treatment of Medically Complex Inflammatory Bowel Disease

Navneet Natt, David Choi, Asher Shafrir, Sushila R Dalal, Noa Krugliak Cleveland, Russell D Cohen, David T Rubin

Digestive Diseases and Sciences · 2026

DOI: 10.1007/s10620-026-09995-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Digestive Diseases and Sciences, 2026. Verfasst von Navneet Natt und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Chicago Medicine Inflammatory Bowel Disease Center, 5841 S. Maryland Avenue, Chicago, IL, MC 4076, USA. Hauptthemen laut MEDLINE: Heterocyclic Compounds, 3-Ring, Antibodies, Monoclonal, Humanized, Crohn Disease, Colitis, Ulcerative. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND AIMS: Dual-targeted therapy (DTT) combines medications with different anti-inflammatory mechanisms to manage immune-mediated conditions. We describe our experience of adding guselkumab (GUS) to upadacitinib (UPA) in complex inflammatory bowel disease (IBD). METHODS: We reviewed our real-world registry of adult patients with IBD who had GUS added to UPA. Prospectively collected outcomes included clinical remission (Harvey-Bradshaw Index (HBI) 5), two achieved clinical remission. Four patients received DTT for CD-associated EIMs and two had partial improvement of symptoms after GUS. All 3 patients who started DTT for active UC achieved clinical remission and one with active enteropathic arthropathy had partial improvement of symptoms after DTT. AEs included minor skin irritation, fatigue, and headaches. 14/15 patients remain on DTT after median 6 months' follow-up. CONCLUSION: The addition of GUS to UPA led to clinical remission in 50% and 100% of patients with CD and UC, and biochemical remission in 55.6% and 66.7% of patients with CD and UC, respectively. 60% noted improvement of their EIMs after adding GUS. No serious AEs were reported highlighting the safety of this DTT strategy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heterocyclic Compounds, 3-RingAntibodies, Monoclonal, HumanizedCrohn DiseaseColitis, UlcerativeGastrointestinal AgentsHumansFemaleAdultMaleTreatment OutcomeRetrospective StudiesMiddle AgedDrug Therapy, CombinationRemission InductionRegistries

Stichwörter der Autor:innen

Crohn’s DiseaseDual-targeted therapyExtraintestinal manifestationsGuselkumabUlcerative colitisUpadacitinib

Substanzen

Heterocyclic Compounds, 3-RingupadacitinibAntibodies, Monoclonal, HumanizedGastrointestinal Agents

Autor:innen und Institutionen

  • Department of Medicine, University of Chicago Medicine Inflammatory Bowel Disease Center, 5841 S. Maryland Avenue, Chicago, IL, MC 4076, USA.
  • Department of Medicine, University of Chicago Medicine Inflammatory Bowel Disease Center, 5841 S. Maryland Avenue, Chicago, IL, MC 4076, USA. drubin@bsd.uchicago.edu.

Zitieren

APA

Natt, N., Choi, D., Shafrir, A., Dalal, S. R., Krugliak Cleveland, N., Cohen, R. D., & Rubin, D. T. (2026). Combining Guselkumab with Upadacitinib Is Safe and Effective in the Treatment of Medically Complex Inflammatory Bowel Disease. Digestive Diseases and Sciences. https://doi.org/10.1007/s10620-026-09995-3

Vancouver

Natt N, Choi D, Shafrir A, Dalal SR, Krugliak Cleveland N, Cohen RD, et al. Combining Guselkumab with Upadacitinib Is Safe and Effective in the Treatment of Medically Complex Inflammatory Bowel Disease. Digestive Diseases and Sciences. 2026. doi:10.1007/s10620-026-09995-3

BibTeX
@article{Natt2026,
  author = {Natt, Navneet and Choi, David and Shafrir, Asher and Dalal, Sushila R and Krugliak Cleveland, Noa and Cohen, Russell D and Rubin, David T},
  title = {Combining Guselkumab with Upadacitinib Is Safe and Effective in the Treatment of Medically Complex Inflammatory Bowel Disease},
  journal = {Digestive Diseases and Sciences},
  year = {2026},
  doi = {10.1007/s10620-026-09995-3}
}
Kostenlos starten →